These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

504 related articles for article (PubMed ID: 35853825)

  • 1. Therapeutic targeting of regulatory T cells in cancer.
    Shan F; Somasundaram A; Bruno TC; Workman CJ; Vignali DAA
    Trends Cancer; 2022 Nov; 8(11):944-961. PubMed ID: 35853825
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanisms of regulatory T cell infiltration in tumors: implications for innovative immune precision therapies.
    Nishikawa H; Koyama S
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34330764
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Small molecule inhibitors targeting regulatory T cells for cancer treatment.
    García-Díaz N; Wei Q; Taskén K
    Eur J Immunol; 2024 Feb; 54(2):e2350448. PubMed ID: 37937687
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of costimulatory and inhibitory receptors in FoxP3
    Toker A; Ohashi PS
    Adv Cancer Res; 2019; 144():193-261. PubMed ID: 31349899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug conjugates for targeting regulatory T cells in the tumor microenvironment: guided missiles for cancer treatment.
    Yang J; Bae H
    Exp Mol Med; 2023 Sep; 55(9):1996-2004. PubMed ID: 37653036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic Regulation of Tregs in Cancer: Opportunities for Immunotherapy.
    Wang H; Franco F; Ho PC
    Trends Cancer; 2017 Aug; 3(8):583-592. PubMed ID: 28780935
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Balancing cancer immunotherapy and immune-related adverse events: The emerging role of regulatory T cells.
    Alissafi T; Hatzioannou A; Legaki AI; Varveri A; Verginis P
    J Autoimmun; 2019 Nov; 104():102310. PubMed ID: 31421963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-coding RNA in tumor-infiltrating regulatory T cells formation and associated immunotherapy.
    Ma Y; Xu X; Wang H; Liu Y; Piao H
    Front Immunol; 2023; 14():1228331. PubMed ID: 37671150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FoxP3
    Saleh R; Elkord E
    Cancer Lett; 2020 Oct; 490():174-185. PubMed ID: 32721551
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulating Treg stability to improve cancer immunotherapy.
    Kang JH; Zappasodi R
    Trends Cancer; 2023 Nov; 9(11):911-927. PubMed ID: 37598003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Colorectal Cancer-Infiltrating Regulatory T Cells: Functional Heterogeneity, Metabolic Adaptation, and Therapeutic Targeting.
    Aristin Revilla S; Kranenburg O; Coffer PJ
    Front Immunol; 2022; 13():903564. PubMed ID: 35874729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tissue-specific Tregs in cancer metastasis: opportunities for precision immunotherapy.
    Huppert LA; Green MD; Kim L; Chow C; Leyfman Y; Daud AI; Lee JC
    Cell Mol Immunol; 2022 Jan; 19(1):33-45. PubMed ID: 34417572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic profiles of regulatory T cells and their adaptations to the tumor microenvironment: implications for antitumor immunity.
    Yan Y; Huang L; Liu Y; Yi M; Chu Q; Jiao D; Wu K
    J Hematol Oncol; 2022 Aug; 15(1):104. PubMed ID: 35948909
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induced regulatory T cells in inhibitory microenvironments created by cancer.
    Whiteside TL
    Expert Opin Biol Ther; 2014 Oct; 14(10):1411-25. PubMed ID: 24934899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Understanding and Targeting Human Cancer Regulatory T Cells to Improve Therapy.
    Kolb HR; Borcherding N; Zhang W
    Adv Exp Med Biol; 2021; 1278():229-256. PubMed ID: 33523451
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treg Fragility: A Prerequisite for Effective Antitumor Immunity?
    Overacre-Delgoffe AE; Vignali DAA
    Cancer Immunol Res; 2018 Aug; 6(8):882-887. PubMed ID: 30068755
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reprogramming of regulatory T cells in inflammatory tumor microenvironment: can it become immunotherapy turning point?
    Liu J; Zhang B; Zhang G; Shang D
    Front Immunol; 2024; 15():1345838. PubMed ID: 38449875
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor resident regulatory T cells.
    Glasner A; Plitas G
    Semin Immunol; 2021 Feb; 52():101476. PubMed ID: 33906820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exhaust the exhausters: Targeting regulatory T cells in the tumor microenvironment.
    McRitchie BR; Akkaya B
    Front Immunol; 2022; 13():940052. PubMed ID: 36248808
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting regulatory T cell metabolism in disease: Novel therapeutic opportunities.
    Halvorson T; Tuomela K; Levings MK
    Eur J Immunol; 2023 Sep; 53(9):e2250002. PubMed ID: 36891988
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.